CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bertagnolo, V.
Right arrow Articles by Capitani, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertagnolo, V.
Right arrow Articles by Capitani, S.
Cell Growth & Differentiation Vol. 12, 193-200, April 2001
© 2001 American Association for Cancer Research

Requirement of Tyrosine-phosphorylated Vav for Morphological Differentiation of All-trans-Retinoic Acid-treated HL-60 Cells1

Valeria Bertagnolo, Marco Marchisio, Federica Brugnoli, Alberto Bavelloni, Luca Boccafogli, Maria Luisa Colamussi and Silvano Capitani2

Signal Transduction Unit-Laboratory of Cell Biology, Section of Human Anatomy, Department of Morphology and Embryology, University of Ferrara, 44100 Ferrara [V. B., M. M., F. B., L. B., M. L. C., S. C.], and Laboratory of Cell Biology and Electron Microscopy, Istituti Ortopedici Rizzoli, 40100 Bologna [A. B.], Italy

Our previous data demonstrated that cellular and nuclear tyrosine-phosphorylated Vav associate with phosphoinositide 3-kinase during all-trans-retinoic acid-dependent granulocytic differentiation of HL-60 cells. In this study, aimed to analyze the mechanism by which Vav is recruited and activated, we report that the Src homology 2 domain of Vav interacts with tyrosine-phosphorylated proteins in a differentiation-dependent manner. Two adaptor proteins, Cbl and SLP-76, were identified, showing a discrete distribution inside the cells, with Cbl absent from the nuclei and SLP-76 particularly abundant in the nuclear compartment. Of note, Vav interacts with the tyrosine kinase Syk, which is also present in the nuclear compartment and may phosphorylate Vav in vitro when cells differentiate. Inhibition of Syk activity by piceatannol prevents both in vitro and in vivo Vav tyrosine phosphorylation, its association with the regulatory subunit of phosphoinositide 3-kinase, and the nuclear modifications typically observed during granulocytic differentiation of this cell line. These findings suggest that tyrosine-phosphorylated Vav and its association with phosphoinositide 3-kinase play a crucial role in all-trans-retinoic acid-induced reorganization of the nucleoskeleton, which is responsible for the changes in nuclear morphology observed during granulocytic differentiation of HL-60 cells.




This article has been cited by other articles:


Home page
J Biol ChemHome page
M. Shen and A. Yen
c-Cbl Tyrosine Kinase-binding Domain Mutant G306E Abolishes the Interaction of c-Cbl with CD38 and Fails to Promote Retinoic Acid-induced Cell Differentiation and G0 Arrest
J. Biol. Chem., September 18, 2009; 284(38): 25664 - 25677.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. Wightman, M. S. Roberson, T. J. Lamkin, S. Varvayanis, and A. Yen
Retinoic Acid-induced Growth Arrest and Differentiation: Retinoic Acid Up-Regulates CD32 (Fc{gamma}RII) Expression, the Ectopic Expression of Which Retards the Cell Cycle
Mol. Cancer Ther., May 1, 2002; 1(7): 493 - 506.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 2001 by the American Association of Cancer Research.